Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) is a global healthcare solutions provider focused on medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. This news page aggregates company announcements, press releases, and other updates related to GE HealthCare’s business activities and capital markets disclosures.
Visitors can find news about GE HealthCare’s collaborations with health systems, governments, and academic institutions, such as agreements to supply advanced CT scanners under national programs, multi-year care alliances with medical centers, and research initiatives in radiation therapy and oncology. The company also issues news on product and technology developments, including imaging systems, AI-powered reconstruction tools, radiology workflow software, and other innovations that it associates with advancing precision care.
GE HealthCare’s news flow includes corporate and investor-focused items as well. Examples include announcements of upcoming earnings releases, participation in healthcare and investor conferences, and responses to shareholder-related matters such as unsolicited mini-tender offers. These communications provide context on how the company presents its strategy, financing activities, and interactions with the capital markets.
Because GE HealthCare emphasizes integrated solutions across Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics, many news items highlight how these businesses work together in specific projects or collaborations. Readers can expect coverage of topics such as AI-enabled imaging, diagnostic access initiatives, training and innovation hubs, and alliances aimed at supporting more efficient and precise care. Investors and observers who follow GEHC news can use this page as a centralized view of the company’s publicly released information and developments over time.
GE HealthCare (Nasdaq: GEHC) reported Q1 2026 results: revenues $5.13B (+7.4% YoY; organic +2.9%), book-to-bill 1.07 and backlog $21.8B. Net income was $389M (diluted EPS $0.85); Adjusted EPS $0.99. Cash from operations $290M; free cash flow $112M. Company closed the $2.3B Intelerad acquisition and reaffirmed organic revenue guidance while reducing profit and free cash flow outlook due to inflation, tariffs and a resolved PDx supplier issue.
GE HealthCare (Nasdaq: GEHC) reorganized operations and executive leadership effective April 29, 2026 to streamline execution, accelerate innovation, and drive growth. The company created Advanced Imaging Solutions (AIS) — a combined Imaging and Advanced Visualization Solutions segment sized at $14.6 billion — led by Phil Rackliffe.
Catherine Estrampes becomes Chief Commercial and Growth Officer to lead a new Global Markets region (all markets except China). Roland Rott will leave the company. GE HealthCare will recast financials to reflect the new segment structure in its Q2 2026 SEC filings.
GE HealthCare (Nasdaq: GEHC) said members of its management team will present at two investor conferences in May and June 2026. Bank of America Health Care Conference presentation is May 12, 2026 at 10:40 am PT / 1:40 pm ET. Jefferies Global Healthcare Conference presentation is June 3, 2026 at 9:20 am ET. Webcasts will be available on the company investor website on the listed dates.
GE HealthCare (Nasdaq: GEHC) announced the first patient was dosed in the international Phase 2/3 LUMINA trial of its manganese-based MRI contrast agent, mangaciclanol, on April 23, 2026.
Mangaciclanol has FDA Fast Track designation for adults and pediatric patients aged 2+, showed tolerability in Phase 1, and demonstrates comparable relaxivity to gadobutrol. The company highlights potential supply and environmental advantages versus gadolinium agents. Mangaciclanol remains investigational and is not approved for clinical use.
GE HealthCare (Nasdaq: GEHC) expanded its collaboration with DeepHealth (RadNet subsidiary) to commercially extend DeepHealth’s AI-powered Breast Suite internationally and integrate new applications with GE’s Pristina Via mammography systems. The deal adds ProFound Pro, Safeguard Review, and cloud-first workflow tools to scale AI-enabled breast cancer screening and second‑reader workflows.
GE HealthCare (NYSE:GEHC) announced a commercial digital integration linking the bkActiv intraoperative ultrasound system with the Medtronic Stealth AXiS surgical navigation system to provide real-time imaging during cranial procedures.
The integration supports plug-and-play visualization to help assess anatomy changes such as brain shift and complements planning, navigation and robotics; the Stealth AXiS has U.S. FDA clearance for cranial procedures.
GE HealthCare (Nasdaq: GEHC) will release first quarter 2026 financial results before market open on Wednesday, April 29, 2026.
The GE HealthCare management team will host a live conference call and webcast at 8:30 a.m. ET the same day. Materials and a replay will be posted on the company investor website.
GE HealthCare (Nasdaq: GEHC) warns shareholders to reject an unsolicited mini-tender by Potemkin Limited offering up to 100,000 shares at $45.80 per share. The offer price is ~34.80% below the $70.25 closing price on March 18, 2026.
The company says the offer contains conditions, potential payment delays, and limited withdrawal rights, urges investors to obtain current market quotations, consult advisors, and take no action if they have not tendered.
GE HealthCare (Nasdaq: GEHC) will serve as the industry lead in COMPASS, a five-year, EU-funded IHI consortium with a total budget of €50.5 million and more than 60 partners to advance early detection and prediction of cardiotoxicity in cancer patients across Europe. The grant agreement was signed on March 25, 2026.
COMPASS will combine AI, advanced imaging, biomarkers and integrated care pathways to develop predictive tools, multi-omics biomarkers and an AI-powered clinical decision support pathway aimed at earlier diagnosis and coordinated cardio-oncology care.
GE HealthCare (Nasdaq: GEHC) will showcase cardiology innovations at ACC.26, including the newly U.S. FDA 510(k) cleared Photonova Spectra photon‑counting CT, ReadyFix fleet management for MAC VU360 ECG workstations, a U.S. collaboration with Gentuity, and recent Allia Moveo regulatory clearances.
Highlights emphasize ultra‑high‑definition imaging, AI‑enabled workflows, intravascular visualization, and operational tools intended to improve diagnostic confidence and device uptime across the cardiac care pathway.